Harvard Bioscience, Inc. (HBIO)
| Market Cap | 280.10M |
| Revenue (ttm) | 105.32M |
| Net Income (ttm) | -3.96M |
| Shares Out | 39.79M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | 24.27 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $6.95 |
| Previous Close | $7.01 |
| Change ($) | -0.06 |
| Change (%) | -0.86% |
| Day's Open | 6.96 |
| Day's Range | 6.90 - 7.03 |
| Day's Volume | 327,763 |
| 52-Week Range | 2.50 - 7.80 |
Harvard Bioscience (HBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow...
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 66.67% and 6.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins
HOLLISTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2021 before the market opens on May 6, ...
Shares of Harvard Bioscience (NASDAQ:HBIO) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to $0.08, which beat the estimat...
On Wednesday, March 10, Harvard Bioscience (NASDAQ:HBIO) will release its latest earnings report. Decipher the announcement with Benzinga's help.
HOLLISTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2020 before the market opens on Marc...
HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 million credi...
HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The B...
Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2020 Results - Earnings Call Transcript
HOLLISTON, MA., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens on Novemb...
HOLLISTON, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values ...
Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2020 Results - Earnings Call Transcript
HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August...
Provides Update on Performance Against Previously Announced Strategic Plan Provides Update on Performance Against Previously Announced Strategic Plan
Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q1 2020 Results - Earnings Call Transcript
Drab Near-Term Prospects for Scientific Instruments Industry
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.
Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders
Harvard Bioscience Introduces Next Generation Inhalation System to Aid in the Fight Against COVID-19
Company will continue to manufacture and ship innovative products for global development and research throughout crisis Company will continue to manufacture and ship innovative products for global devel...
Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q4 2019 Results - Earnings Call Transcript
Scientific Instruments Industry Outlook: Prospects Look Good
Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.
Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2019 Results - Earnings Call Transcript
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and -3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
HOLLISTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Yash Singh being named Executive Vice President, Cellular & Molecula...
HOLLISTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, ...
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOLLISTON, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI)...
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2019 Results - Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) CEO Jeffrey Duchemin on Q1 2019 Results - Earnings Call Transcript
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -33.33% and -0.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equi... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Dec 7, 2000 |
| Stock Exchange NASDAQ | Ticker Symbol HBIO |
Financial Performance
In 2020, HBIO's revenue was $102.10 million, a decrease of -12.12% compared to the previous year's $116.18 million. Losses were -$7.81 million, 66.6% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for HBIO stock is "Strong Buy." The 12-month stock price forecast is 9.75, which is an increase of 40.29% from the latest price.